Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome

Alexandra Laberko1 · Ekaterina Deordieva1 · Gergely Krivan2 · Vera Goda2 · Saleh Bhar3 · Yuta Kawahara4 · Kanchan Rao5 · Austen Worth5 · David H. McDermott6 · Dmitry Balashov7 · Alexey Maschan7 · Anna Shcherbina1

Received: 8 April 2021 / Accepted: 11 October 2021 / Published online: 26 October 2021 © The Author(s) 2021

Abstract
Purpose WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare disease, caused by CXCR4 gene mutations, which incorporates features of combined immunodeficiency, congenital neutropenia, and a predisposition to human papillomavirus infection. Established conventional treatment for WHIM syndrome does not fully prevent infectious complications in these patients. Only single case reports of hematopoietic stem cell transplantation (HSCT) efficacy in WHIM have been published.

Methods To summarize current information on HSCT efficacy in disease treatment, seven pediatric patients with WHIM syndrome who underwent allogeneic HSCT were identified in five centers worldwide.

Results All patients presented early after birth with neutropenia. Two of seven patients exhibited severe disease complications: poorly controlled autoimmunity (arthritis and anemia) in one and progressive myelofibrosis with recurrent infections in the other. The remaining patients received HSCT to correct milder disease symptoms (recurrent respiratory infections, progressing thrombocytopenia) and/or to preclude severe disease course in older age. All seven patients engrafted but one developed graft rejection and died of infectious complications after third HSCT. Three other patients experienced severe viral infections after HSCT (including post-transplant lymphoproliferative disease in one) which completely resolved with therapy. At last follow-up (median 6.7 years), all six surviving patients were alive with full donor chimerism. One patient 1.4 years after HSCT had moderate thrombocytopenia and delayed immune recovery; the others had adequate immune recovery and were free of prior disease symptoms.

Conclusion HSCT in WHIM syndrome corrects neutropenia and immunodeficiency, and leads to resolution of autoimmunity and recurrent infections, including warts.

Keywords WHIM syndrome · primary immunodeficiency · congenital neutropenia · human papillomavirus · warts · hematopoietic stem cell transplantation

1 Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1, Samory Mashela str, 117997 Moscow, Russia
2 Department for Pediatric Hematology and Hemopoietic Stem Cell Transplantation, Central Hospital of Southern Pest- National Institute of Hematology and Infectious Diseases, Budapest, Hungary
3 Department of Pediatric Hematology Oncology and Critical Care Medicine, Pediatric Bone Marrow Transplantation, Texas Children`s Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, USA
4 Department of Pediatric, Jichi Medical University School of Medicine, Tochigi, Japan
5 Department of Immunology and Bone Marrow Transplantation, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
6 Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
7 Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
**Introduction**

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare autosomal dominant primary immunodeficiency (PID), caused by CXCR4 gene mutations [1]. CXCR4 is a chemokine receptor expressed by hematopoietic stem and progenitor cells, mature leukocytes, and some non-hematopoietic cells [2]. CXCR4 gene gain of function mutations in WHIM syndrome lead to a phenotype of combined immunodeficiency and abundant mature apoptotic neutrophil accumulation in bone marrow, or myelokathexis, resulting in neutropenia in peripheral blood [3]. Although the acronym WHIM is formed by classic disease symptoms, a recent review of WHIM syndrome patients by Heusinkveld et al. found myelokathexis to be the only pathognomonic sign detectable in all patients [4]. Other clinical presentations vary and include bacterial upper and lower respiratory tract and skin infections, human papillomavirus (HPV) positive warts, as well as laboratory findings such as neutropenia, lymphopenia, hypogammaglobulinemia, and thrombocytopenia. Despite the features of combined primary immunodeficiency (PID), opportunistic infections other than HPV are not common in WHIM syndrome. Up to 18% of patients develop autoimmunity (Geier CB et al, submitted), and up to 30% develop lymphoid and HPV-related malignancies at an older age (19–65 years) [5,6].

While hematopoietic stem cell transplantation (HSCT) is a well-established option to cure a variety of PID [7], only a few single case reports reporting a curative effect of HSCT in WHIM syndrome have been published so far [8–10].

The current study describes a multicenter HSCT experience in a series of patients with WHIM syndrome.

**Patients and Methods**

Seven pediatric patients with WHIM syndrome who underwent allogeneic HSCT were identified in five centers worldwide (Table 1) and retrospectively included in the current study. The details of disease presentation in P4 [11], HSCT information and outcomes of P3, P4, and P5 [8,9,12,13] were previously published.

The main characteristics of the patients and details of disease presentation are shown in Table 1. All patients presented early after birth (median age of disease onset 0.85 years) with neutropenia. Myelokathexis in bone marrow was later demonstrated in 6/7 (was not investigated in one). In the course of the disease, 5/7 patients developed thrombocytopenia and 3/7 anemia, presumed to be of immune origin in all but one. In P6, cytopenia (progressive anemia, thrombocytopenia and the need of increasing doses of granulocyte – colony stimulating factor (G-CSF)) was caused by bone marrow reticulin fibrosis. Five patients had lymphopenia with a substantial decrease of both CD3+ and CD19+ cells. Hypogammaglobulinemia was found in 6/7. Patients’ pre-HSCT blood counts, lymphocyte subsets, and immunoglobulins levels are shown in Table 2. Five patients experienced upper and/or lower respiratory tract infections that resolved without sequelae; three patients developed skin and intestinal infections. P6 developed mild cutaneous warts at the age of three years; no HPV infection was observed in the other patients. P3 had rheumatoid arthritis and Coombs-negative autoimmune hemolytic anemia.

Six of seven patients were treated with routine intravenous immunoglobulin (IVIG) replacement and 5/7 received G-CSF therapy to correct neutropenia (Table 3); 6/7 patients were on antimicrobial prophylaxis. The median age of IVIG and G-CSF initiation was 1.8 years. P3 received a combination of steroids (maximum dose of methylprednisolone 2 mg/kg/day) and cyclosporin A to control arthritis and autoimmune hemolytic anemia. While on immunsuppressive therapy, P3 developed cytomegalovirus (CMV) viremia and received ganciclovir until HSCT, and foscarnet in the post-HSCT period.

In all patients, the diagnosis of WHIM was confirmed by detection of CXCR4 gene mutations (Table 1). In P1 and P2, CXCR4 gene mutations were found by custom-panel sequencing performed using a next-generation sequencing method and subsequently confirmed by Sanger sequencing, while in P3, P4, P5, P6, and P7, only Sanger sequencing was used. All, but P7, mutations were previously investigated functionally; each of them results in a truncated receptor, which was described elsewhere. The mutation in P7 is predicted to result in the truncated protein.

Four patients had de novo mutations of the CXCR4 gene and in three patients, it was inherited from an affected parent. The disease course in affected parents varied: P6’s mother had only warts and recurrent pneumonia, while P1’s mother had debilitating frequent lower respiratory tract and soft tissue infections with extensive warts. P7’s father had frequent lower respiratory tract infections, tuberculosis, and both P6 and P7 parents required regular hospital admissions and/or surgical treatment. CXCR4 gene mutations were excluded in the family donors of P2 and P4 before HSCT.

For donor chimerism, real-time quantitative polymerase chain reaction (PCR) assessment of the insertion/deletion short tandem repeats or variable number tandem repeats polymorphisms was performed. The presence of more than 95% donor-derived cells in peripheral blood was considered as full donor chimerism.
| Patient # | Center* | Sex | Disease onset | CXCR4 mutation** | Age at CXCR4 mutation detection | CXCR4 mutation inheritance | Disease symptoms | Other infections | Developmental defects | Other symptoms |
|-----------|---------|-----|---------------|------------------|-------------------------------|----------------------------|-------------------|----------------|---------------------|---------------|
| P1        | Russia  | M   | at birth      | c.1000C>T        | 7 mon                        | From affected mother         | Yes               | No             | No                  | No            | Ductus arteriosus, nephromegaly, hydrocele, NDD |
| P2        | Russia  | M   | 2 months      | c.1027G>T        | 5 y                          | De novo                     | Yes               | No             | No                  | Yes           | Acute gastroenteritis, Severe combined heart defect, ectopic left kidney, inferior vena cava duplication, joint hypermobility, NDD |
| P3        | Russia  | F   | 4 months      | c.970_971insTCCT | 4.3 y                        | De novo                     | Yes               | No             | No                  | Yes           | Furunculosis, CMV viremia, Growth delay, umbilical hernia, talipes valgus |
| P4        | Hungary | F   | 1 year        | c.1013C>G        | 5.5 y                        | De novo                     | Yes               | No             | No                  | No            | No |
| P5        | Japan   | F   | 10 months     | c.1000C>T        | 1 y                          | De novo                     | Yes               | No             | No                  | No            | No |
| P6        | USA     | F   | at birth      | c.969_970insG    | 2 y                          | From affected mother         | Yes               | Yes            | Yes                  | Yes           | No |

* Center of origin
** CXCR4 mutation described by cDNA position and base change

Table 1 Patients’ characteristics
Neutrophil engraftment was registered on the first of three consecutive days of an absolute neutrophil count above $0.5 \times 10^9/\text{l}$, and platelet engraftment was registered on the first of three days of platelet counts more than $20 \times 10^9/\text{l}$ without platelet transfusions for seven consecutive days. Loss of donor cells following established engraftment, proven by detection of more than 90% of recipient chimerism in the peripheral blood, was defined as graft failure.

For graft-versus-host disease prophylaxis, TCRαβ+/CD19+ graft depletion was used in P1, P2, and P3. The depletion was performed via Miltenyi Biotec (Bergisch Gladbach, Germany) instructions.

Anti-Epstein-Barr virus (EBV) cytotoxic T-lymphocytes (CTL) used in P7 were generated and stored by the CTL bank held at the University of Aberdeen, UK, in association with the Scottish Blood Transfusion service, according to the described earlier methodology [14].

## Results

In most of the patients, poor disease control (detailed in Table 3) served as indication for HSCT and other patients received HSCT preemptively to prevent the risk of malignancies and to preclude the severe disease course observed in the affected parent. The median age at HSCT was 3.7 years (range 1.4–9.3). All patients described received allogeneic HSCT using different approaches (the details of donors, graft source and composition, conditioning regimens, and post-transplant immunosuppression are shown in Table 3).

The median current follow-up post-HSCT in survivors is 6.7 years (1.4–12.8). All patients engrafted; the median of both neutrophil and platelet engraftment was day + 15 (Table 3). At day +27, P1 developed graft rejection and in five months received a second HSCT from an alternative unrelated donor. Neutrophil and platelet engraftment occurred at day + 17 and + 16, respectively, which was followed by poor graft function and rejection at day + 72. After the second graft rejection, the patient remained neutropenic and lymphopenic and developed poorly controlled multiple infections (adenovirus (ADV) viremia, roto-/noroviral, ADV enterocolitis, *Clostridium difficile* colitis). Due to the absence of alternative curative options, a third allogeneic HSCT from another unrelated donor was performed, followed by non-engraftment and death from disseminated ADV infection at day + 20. All second and third HSCT details are shown in Table 4.

P7 at one month post-HSCT developed grade II skin acute graft-versus-host disease (GVHD), which responded well to 1 mg/kg/day steroid therapy. Despite patient and donor being EBV negative pre-transplant, during the steroid tapering, at day + 56, the patient developed EBV viremia with 2.4 million EBV copies per ml of blood, accompanied by

| Table 1 (continued) | Patient # | Center | Sex | Disease onset | Age at HSCT | CXCR4 mutation | CXCR4 mutation inheritance | Graft failure | Disease symptoms | Other symptoms | Disease symptoms | Neutrophilia | Neutrophilia/myelokathexis | Otorhinolaryngological infections | Other infections | Disease symptoms | Developmental defects | Other symptoms | Disease symptoms | Neutrophilia | Neutrophilia/myelokathexis | Otorhinolaryngological infections | Other infections | Disease symptoms | Developmental defects | Other symptoms |
|----------------------|-----------|-------|-----|---------------|-------------|-----------------|--------------------------|---------------|-----------------|---------------|-----------------|---------------|--------------------------|-----------------------------|---------------|-----------------|--------------------------|---------------|-----------------|---------------|--------------------------|-----------------------------|---------------|-----------------|--------------------------|---------------|-----------------|--------------------------|---------------|
| P7                   | UK        | F     | birth | 7 mon        | From affected father | c.954delC | Neutrophilia/myelokathexis | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No |

*F Female, M male, HPV human papilloma virus, NDD neurodevelopmental delay

**Based on CXCR4 sequence given in NM_003467.2 and 003467.3

***Neutrophilia/myelokathexis detected by bone marrow investigation to demonstrate myeloablation was performed.

**F Female, M male, HPV human papilloma virus, NDD neurodevelopmental delay

---

---

Journal of Clinical Immunology (2022) 42:171–182
Table 2  Patients pre- and post- HSCT laboratory parameters

| Patient # | HSCT Age/time after HSCT | Whole blood counts x 10⁹/l | Lymphocyte subsets x 10⁹/l | Immunoglobulin levels, g/l |
|-----------|--------------------------|-----------------------------|-----------------------------|---------------------------|
|           |                          | WBC  PMN  PLT**  Lymph     | CD3+  CD4+  CD8+  CD19+  CD3-16+56+ | IgG  IgM  IgA               |
| P1        | Pre 3 months             | 3.92  0.17  285 (44) 3.61 | 1.57  1.19  0.29  0.62  1.02 | 2.86  1.11  0.34             |
|           | Post                     | -                -          -     | -                -          -     | -                -          -     |
| P2        | Pre 1.9 years            | 1.1  0.08  167 (51) 0.87 | 0.88  0.74  0.06  0.23  0.31 | 2.2  0.8  0.2               |
|           | Post +1.4 years          | 2.63  1.8  88 0.55 | 0.42  0.24  0.07  0.12  - | 6.3  0.87  0.31             |
| P3        | Pre 2.7 years            | 0.63  0.04  217 (22) 0.49 | 0.38  0.26  0.09  0.03  0.12 | 3.99  0.23  0.27             |
|           | Post +5.7 years          | 7.34  3.44  311 3.05 | 2.28  0.84  1.32  0.53  0.18 | 10.6  1.5  1.2               |
| P4        | Pre 5 years              | 2.4  0.61  265 1.92 | -  0.54  0.1  0.04  0.11 | 4.02  0.45  0.43             |
|           | Post +12.6 years         | 6.7  3.9  209 2.26 | 1.7  0.95  0.57  0.24  0.15 | 6.7  0.85  0.96             |
| P5        | Pre 3 years              | 0.5  0.01  189 0.46 | 0.25  0.18  0.04  0.02  0.15 | 2.7  0.61  0.48             |
|           | Post +5 years            | 5  2.2  177 2.45 | 2.13  0.95  1.03  0.31  - | 8.6  0.8  0.62             |
| P6        | Pre 3.8 years            | 2.93  1.16  41 1.2 | 0.63  0.42  0.17  0.14  0.15 | 2.2*  0.99*  0.56*         |
|           | Post +6.5 years          | 6.6  3.2  258 2.9 | 1.6  0.92  0.62  0.54  0.08 | 12.1  1.7  0.78             |
| P7        | Pre 7 months             | 3.6  0.1  394 3.4 | 2.06  1.63  0.4  0.15  0.01 | 5.2  0.9  0.5               |
|           | Post +2 years            | 6.6  2.2  292 2.22 | 1.87  1.04  0.78  0.15  0.16 | 7.6  0.71  0.64             |

WBC white blood cells, PMN polymorphonuclear leukocytes (neutrophils), PLT platelets, lymph lymphocytes

As normal ranges for ages varied between different laboratories, abnormal values were highlighted with italic. In all, but P6, immunoglobulin levels were tested before immunoglobulin replacement and G-CSF therapy initiation.

*P6 pre-HSCT immunoglobulin levels were tested at the age of 1.8 years

**Pre-HSCT platelet values in P1, P2, and P3 are displayed in parentheses
### Table 3: Hematopoietic stem cell transplantation details

| Patient # | Pre-HSCT therapy | Age at therapy initiation, years | Reason for HSCT | Age at HSCT, years | Conditioning regimen | Conditioning type** | GVHD prophylaxis | Donor HLA match | Stem cell source | Graft manipulation | Graft composition*** | Engraftment, days | HSCT outcome |
|-----------|------------------|----------------------------------|-----------------|-------------------|---------------------|---------------------|-------------------|-----------------|----------------|------------------|-------------------|-----------------|--------------|
| P1        | IVIG G-CSF 8/d azithromycin flucona-zole | 0.25                | Poor response to high doses of G-CSF, worsening thrombocytopenia | 1.4               | Treo 42 Flu 150 TT 10 Thymo 5 Rit 100 | MAC               | No                | MUD 10/10        | PBSC             | TCRαβ+/CD19+ depletion | 7.16 10.53 16.76 (15.75) | +12 +15       | Graft rejection d+27, died post 3rd HSCT |
| P2        | IVIG G-CSF 11/d SMP/ TMP flucona-zole | 1.8                 | Worsening neutropenia and thrombocytopenia | 5.8               | Treo 42 Flu 150 TT 10 Thymo 5 Rit 100 | MAC               | No                | MMFD 5/10        | PBSC             | TCRαβ+/CD19+ depletion | 15.4 10.64 18.54 (51.5) | +17 +15       | Alive 1.4 years |
| P3        | IVIG G-CSF 20/d SMP/ TMP flucona-zole CsA, steroids | 2.8                 | Poor control of autoimmunity, worsening neutropenia | 3.7               | Treo 42 Flu 150 ATGAM 90 | RIC               | Tacro d+60 Mtx   | MUD 10/10        | PBSC             | TCRαβ+/CD19+ depletion | 8.05 14.0 19.0 (0.8) | +15 +12       | Alive 8 years    |
| P4        | IVIG G-CSF 5/2d | 5.5                 | Recurrent infections, worsening neutropenia | 9.3               | Bu 12 Cy 200 Thymo 5 | RIC               | Mpred d+27 CsA d+384 | MSD 12/12        | UCB              | No               | 0.36 0.12 0.75 | +32 +38        | Alive 12.8 years |
| P5        | IVIG | 1                  | Pre-emptively | 3.8               | Mel 140 Flu 125 TBI 3Gr | RIC               | Tacro d+30 CsA d+180 Mtx | MMFD 7/8        | BM               | No               | 0.72 3.34 –     | +14 +21        | Alive 5.7 years  |
Table 3 (continued)

| Patient # | Pre-HSCT therapy | Age at therapy initiation, years | Age at HSCT, years | Conditioning regimen | Conditioning type** | GVHD prophylaxis | Donor HLA match | Stem cell source | Graft manipulation | Graft composition*** | Engraftment, days | HSCT outcome |
|-----------|------------------|---------------------------------|-------------------|---------------------|---------------------|-------------------|-----------------|----------------|------------------|------------------|----------------|-------------|
| P6        | IVIG G-CSF 5-8/d cefuroxime | 1.9 1 month | 4.3 | Bu* Cy 200 Alem* | MAC | Tacro d+100 Mtx | MUD 10/10 BM No | 7.5 7.2 | – | +23 +29 | Alive 7.7 years |
| P7        | itraconazole, azithromycin, ciprofloxacin | – | 2.6 | Pre-emptively | Treo 36 Flu 150 Alem 1 | RIC | CsA d+110 MMF d+60 | MUD 12/12 PBSC No | 33.7 50 | 780 | +13 +12 | Alive 2.7 years |

IVIG intravenous immunoglobulin, G-CSF granulocyte – colony stimulating factor (doses in μg/kg/days), TMP/SMX trimethoprim/sulfamethoxazole, MUD matched unrelated donor, MMFD mismatched family donor, MSD matched sibling donor, UCB umbilical cord blood, PBSC peripheral blood stem cells, BM bone marrow, GVHD graft-versus-host disease, MMF mycophenolate mofetil, NC nucleated cells, Neut neutrophil, Plt platelet

Treo treosulfan, g/m²; TT thioptepa, mg/kg; Flu fludarabine, mg/m²; Cy cyclophosphamide, mg/kg; Bu busulfan, mg/kg; Mel melphalan, mg/m²; TBI total body irradiation; Thymo thymoglobulin, mg/kg; Alem alemtuzumab, mg/kg; Rit rituximab, mg/m²; ATGAM mg/kg; CsA cyclosporin A, Tacro tacrolimus, MMF mycophenolate mofetil, Mpred methylprednisolone, Mtx methotrexate 10mg/m² days +1, +3, +6

GVHD prophylaxis is indicated with days of withdrawal. Serotherapy timing was as follows: in P1, P2, P3 days – 5 to – 4, in P4 days – 4 to – 1, in P6 days – 5 to – 2, in P7 days – 8 to – 4

*The total doses of busulfan and alemtuzumab given were 0.8 mg/dose 16 times and 5 mg/dose 4 times (adjusted for 15.1-30 kg body weight), respectively

**According to Shaw et al. definition [17]

***The numbers of TCRαβ+ cells x10⁶/kg are displayed in CD3+ column in parenthesis
ADV viremia which resolved after cidofovir therapy. EBV infection did not respond to rituximab treatment (375 mg/m² given once a week 4 times). At day +95, while steroids and mycophenolate mofetil had ceased, and cyclosporin A was being weaned (lymphocyte count at the time 0.25–0.45 \times 10^9/l), repeated investigations showed liver lesions, extensive mediastinal and mesenteric lymphadenopathy, and bowel wall thickening. A low level of EBV was detected in the cerebrospinal fluid, with no lesions found in the brain by magnetic resonance imaging. An abdominal mass biopsy revealed CD20+ EBV+ polymorphic post-transplant lymphoproliferative disease (PTLD) of predominantly recipient cell origin, despite full donor chimerism in the peripheral blood (PTLD morphology is shown in Picture 1). The patient received chemotherapy with cyclophosphamide, vincristine, and prednisolone. The treatment was complicated by vancomycin-resistant Enterococcus bacteremia, which resolved upon antimicrobial treatment, and posterior reversible encephalopathy. No response to 2 cycles of chemotherapy was seen, with persistent lymphadenopathy, liver lesions, and EBV viremia. Finally, a third-party donor anti-EBV specific CTL infusion was performed, which led to complete resolution of PTLD, confirmed by repeat blood EBV PCR, imaging of abdominal lymphadenopathy and liver lesions, and bone marrow aspirate.

No life-threatening post-HSCT complications were observed in the other patients. P6 had acute grade II skin GVHD, which resolved with steroid therapy. Later, she experienced transient ADV and human herpes virus-7 viremia, mild BK virus cystitis, and Corynebacterium bacteremia. Resolution of warts in P6 was observed by 4–6 months post-HSCT with no additional therapy. About a year after HSCT, she developed several molluscum contagiosum lesions, which resolved with liquid nitrogen cryotherapy and an antiviral cream.

At day +11, P3 developed reactivation of pre-existing CMV viremia, followed by BK virus cystitis. Despite CMV viremia resolution and immunosuppression cessation, after discontinuation of antiviral therapy, at day +71, CMV viremia recurred and at day +88, a retinal inflammatory focus was found. Both CMV viremia and retinitis of presumed CMV etiology resolved on antiviral therapy. Except for P6 and P7, no other patients had grade II-IV acute or chronic GVHD.

In the early post-HSCT period, despite full donor chimerism, P2 remained thrombocytopenic with maximum level of platelets 90 \times 10^9/l. At 4.5 months post-HSCT, romiplostim therapy was initiated with good, but short-term response. At 9 months post-HSCT, thrombocytopenia responded well to treatment with several courses of high dose IVIG. However, at last follow-up, 1.4 years after HSCT, the patient still has moderate thrombocytopenia and delayed lymphocyte recovery; however, he is free of infections and does not require
IVIG replacement. In the other patients, all baseline hematologic and immune manifestations of WHIM syndrome resolved after HSCT.

All six surviving patients achieved full donor whole blood chimerism after HSCT. At last follow-up, all retained complete donor chimerism and were independent of immunoglobulin replacement. All but P2 had adequate immune recovery and were free of any symptoms of prior disease. Patients’ post-HSCT blood counts, lymphocyte subsets, and immunoglobulin levels are shown in Table 2. P3 had growth delay, P4 immune hypothyroidism and hypogonadism requiring hormonal replacement therapy. No long-term complications in the other patients were observed. In P4 cervical investigation, performed at long-term post HSCT follow-up, revealed no pathologic findings.

Discussion

WHIM syndrome is a rare congenital disease, which incorporates features of combined immunodeficiency, congenital neutropenia, and predisposition to HPV infection [15]. Conservative therapy with immunoglobulin replacement, G-CSF, and more recently plerixafor does not provide complete control of infectious and autoimmune episodes in WHIM patients [4], (Geier CB et al, submitted) and cannot prevent malignancies [5]. HSCT is a well-established treatment option for many PIDs. As case series of WHIM syndrome are scarce, there are no agreed indications for HSCT specifically determined for this disorder. We retrospectively collected the data of seven pediatric patients with WHIM syndrome, who received HSCT for a variety of reasons and with diverse approaches used.

Of seven reported patients, one died of infectious complications following two graft rejections. Graft failure is relatively common after HSCT in congenital neutropenia [16]. P1 in our study developed graft rejection, despite a myeloablative conditioning regimen [17]. However, most of the patients in the group received reduced intensity conditioning regimens and did not experience severe graft dysfunction, although a potential role of TCRαβ+/CD19+ graft depletion used in P1 must be also considered in graft rejection [12]. Moreover, P1 developed rejection after the second and third HSCT with more immunosuppressive conditioning regimens, also containing plerixafor. Plerixafor was shown to partially correct neutropenia and lymphopenia in WHIM syndrome [18, 19] and to facilitate stem cell engraftment in some disorders [20, 21]. None of the measures improved the second HSCT outcomes in P1. To evaluate the impact of conditioning regimen type and T-cell elimination methods on graft function in WHIM patients after HSCT, a larger group of patients needs to be studied.

The incidence of EBV-related lymphoid malignancies is increased in WHIM patients [22–24]. None of the patients in our study had malignancies pre-HSCT, which might be due to their young age at the time of HSCT. However, one patient developed EBV-driven polymorphic PTLD of recipient cell origin despite being EBV negative pre-HSCT. Four of seven patients in our study experienced significant viral infections post-HSCT, although in one, severe infections followed graft
resolution completely 1.5 years post-HSCT [10]. In the current study, the patient who exhibited warts before HSCT demonstrated complete resolution of warts at 4–6 months after HSCT. One patient experienced post-HSCT mild molluscum contagiosum, but none of five surviving patients who had no warts pre-HSCT developed HPV infection after HSCT. Nevertheless, longer follow-up and larger series of patients are needed to estimate the risk of HPV infection and both HPV-related and non-related malignancies in WHIM syndrome after HSCT. Interestingly, although T cells play an important role in anti-HPV immunity [27], a WHIM patient in whom a chromothripsis event corrected defective myelopoiesis, but not lymphopoiesis, cleared HPV infection [28]. This suggests that myeloid cells might play a major role in HPV control in WHIM syndrome. Since all our patients had full donor chimerism at the last follow-up, the level of donor lymphocyte and myeloid lineage chimerism needed to control WHIM syndrome symptoms remains uncertain.

Interestingly, reticulin myelofibrosis observed in P6 was earlier described only in older patients after long-term G-CSF treatment [10, 19]. Severe neutropenia in WHIM syndrome seems to cause less fatal infectious complications, observed in other severe congenital neutropenia, due to neutrophil mobilization from bone marrow to peripheral blood during bacterial infection episodes [5]. However, the risks of myelofibrosis on prolonged G-CSF therapy are of concern. Plerixafor therapy, allowing G-CSF cessation, was demonstrated to ameliorate fibrotic changes in adult patients [19], although plerixafor so far is not widely available for pediatric patients. Notably, P2 a year post-HSCT remains mildly thrombocytopenic and with delayed immune recovery. Due to good response to IVIG therapy, his thrombocytopenia was suspected to be of immune origin, although no bone marrow trephine investigation was performed pre- and post-HSCT to exclude myelofibrosis. Longer follow-up is needed to evaluate platelet and lymphocyte counts in this patient.

Although HSCT in adult patients with longer history of infections and multiple comorbidities might lead to higher risks of post-HSCT complications, Moens et al. reported successful HSCT of an adult patient with WHIM syndrome with a history of refractory warts, recurrent herpes simplex virus infection, and myelofibrosis [10]. Due to improving results of HSCT in PID and better HSCT outcomes in younger patients without poorly controlled disease complications and associated disorders, the modern standard of PID care is to consider HSCT in patients at risk of life-threatening complications before their development [7]. In our case series, only two of seven WHIM syndrome patients exhibited severe disease complications: poorly controlled autoimmunity and immunosuppression-related CMV infection in one and progressive myelofibrosis and recurrent infections in another. Other patients received HSCT to correct milder disease symptoms and/or to preclude severe disease course seen, either in parents or reported in the literature.

Based on our data, HSCT in WHIM syndrome patients cannot be considered as a completely safe treatment and risks of life-threatening transplant-related complications and death still remain. However, no other treatment options capable of preventing an often devastating disease course are currently available for WHIM. Regular plerixafor therapy does not seem to completely resolve all disease complications [19], while our transplantation experience demonstrates complete resolution of the majority of disease symptoms. Although there is evidence of possible gene therapy efficacy in WHIM syndrome mouse models [29], so far, allogeneic HSCT remains the only curative option for WHIM syndrome patients. Therefore, based on our experience of HSCT and subsequent short-term follow-up, we believe that HSCT can be considered as a treatment option for WHIM syndrome, including pre-emptive indications in younger patients, before they develop autoimmunity and malignancies at an older age.

Conclusions

Allogeneic HSCT in WHIM syndrome corrects neutropenia and immunodeficiency, and leads to resolution of autoimmunity and recurrent infections, including warts. However, taking in account potential risks of transplant-related mortality, before larger HSCT experience series with longer follow-up will become available, the decision to perform a HSCT in WHIM syndrome patients must be made individually.

Acknowledgements The authors acknowledge Dr Samantha Levine, consultant histopathologist at Great Ormond Street Hospital, London, for preparation of P7’s PTLD morphology pictures.

Author Contribution AL collected, analyzed, and interpreted the patients’ data and prepared the manuscript. ED, GK, VG, SB, YK,
KR, AW, DHM, and DB contributed to patient care and data collection. AM led the HSCT program used for P1, P2, and P3. AS conducted the study and edited the manuscript. All authors read and approved the final manuscript.

Data Availability The dataset used during the current study is available from the corresponding author on reasonable request.

Declarations This project was partially supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Ethics Approval The study was approved by local independent ethics committees.

Consent to Participate Institutional consent forms were obtained from all patients.

Consent for Publication Institutional consent forms were obtained from all patients.

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34(1):70–4.
2. Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett. 2016;177:6–15.
3. McDermott DH, Murphy PM. WHIM syndrome: immunopathogenesis, treatment and cure strategies. Immunol Rev. 2019;287(1):91–102.
4. Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM Syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.
5. Dotta L, Notarangelo LD, Moratto D, Kumar R, Porta F, Soresina A, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol: Pract. 2019;7(5):1568–77.
6. Beaussant Cohen S, Fenetxeau O, Plouvier E, Rohrlich P-S, Dal troff G, Plantier I, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7(1):71.
7. Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295.
8. Kriván G, Erdős M, Kállay K, Benyó G, Tóth Á, Sinkó J, et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol. 2010;84(3):274–5.
9. Kawahara Y, Oh Y, Kato T, Zaha K, Morimoto A. Transient marked increase of γδ T cells in WHIM syndrome after successful HSCT. J Clin Immunol. 2018;38(5):553–5.
10. Moens L, Frans G, Bosch B, Bossuyt X, Verbinnen B, Poppe W, et al. Successful hematopoietic stem cell transplantation for myeloblastosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome. J Allergy Clin Immunol. 2016;138(5):1485-1489.e2.
11. Alapi K, Erds M, Kovács G, Maródi L. Recurrent CXCR4 sequence variation in a girl with WHIM syndrome. Eur J Haematol. 2007;78(1):86–8.
12. Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955–62.
13. Laberko A, Sultanova E, Goutovskaya E, Shipitsina I, Shelikhova L, Kurnikova E, et al. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies. Blood. 2019;134(20):1755–63.
14. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, et al. Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167(3):402–10.
15. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.
16. Fioredda F, Iacobelli S, van Biezen A, Gaspar B, Ancliff P, Donadieu J, et al. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood. 2015;126(16):1885–92.
17. Shaw P, Shizuru J, Hoening M, Veys P. IEWP-EBMT conditioning perspectives for primary immunodeficiency stem cell transplants. Front Pediatr. 2019;7:434.
18. McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O’Brien S, Ulrick J, et al. Phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308–16.
19. McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380(2):163–70.
20. Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Goutovskaya E, et al. A conditioning regimen with Plerixafor is safe and improves the outcome of TCRαβ+ and CD19+ cell-depleted stem cell transplantation in patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018;24(7):1432–40.
21. Maganti H, Visram A, Shorr R, Fulcher J, Sabloff M, Allan DS. Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: a systematic review and metaanalysis of preclinical and clinical studies. Leuk Res. 2020;97:106442.
22. Chae KM, Ertle JO, Tharp MD. B-cell lymphoma in a patient with WHIM syndrome. J Am Acad Dermatol. 2001;44(1):124–8.
23. Imashuku S, Miyagawa A, Chiyonobu T, Ishida H, Yoshihara T, Teramura T, et al. Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Ann Hematol. 2002;81(8):470–3.

24. Zhang A, Chen X, Li Z, Ruan M, Zhang Y, Zhu X. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome. Pediatr Blood Cancer [Internet]. 2019 [cited 2020 Nov 14];66(11). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.27951.

25. Hiwarkar P, Gajdosova E, Qasim W, Worth A, Breuer J, Chiesa R, et al. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. Clin Infect Dis. 2014;58(12):1700–6.

26. Laffort C, Deist FL, Favre M, Caillat-Zucman S, Radford-Weiss I, Fraitag S, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency. Lancet. 2004;363(9426):2051–4.

27. Leiding JW, Holland SM. Warts and all: Human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130(5):1030–48.

28. McDermott DH, Gao J-L, Liu Q, Siwicki M, Martens C, Jacobs P, et al. Chromothriptic cure of WHIM syndrome. Cell. 2015;160(4):686–99.

29. Gao J-L, Owusu-Ansah A, Paun A, Beacht K, Yim E, Siwicki M, et al. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice. JCI Insight. 2019;4(24):e132140.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.